Cascade Programming for 10 kHz Spinal Cord Stimulation: A Single Center Case Series of 114 Patients With Neuropathic Back and Leg Pain
Autor: | Katie Markham, Omar Al-Kaisy, Stefano Palmisani, Adnan Al-Kaisy, David Pang, Jonathan Royds, Stephany Harris, Thomas L. Yearwood, Samuel Wesley, Nick Padfield, Thomas Smith |
---|---|
Rok vydání: | 2021 |
Předmět: |
Series (stratigraphy)
business.industry Inadequate Pain Relief Chronic pain Leg pain General Medicine Spinal cord stimulation medicine.disease Single Center 03 medical and health sciences 0302 clinical medicine Anesthesiology and Pain Medicine Neurology Cascade Anesthesia medicine Neurology (clinical) business Lead (electronics) 030217 neurology & neurosurgery |
Zdroj: | Neuromodulation: Technology at the Neural Interface. 24:488-498 |
ISSN: | 1094-7159 |
DOI: | 10.1111/ner.13219 |
Popis: | OBJECTIVE Ten kilohertz spinal cord stimulation (SCS) is usually initiated in a single-bipolar configuration over the radiological reference point T9/T10 intervertebral disc space for neuropathic back and leg pain. Cascade is a duty-cycled, multi-bipolar contact configuration across an entire eight-contact lead. Potential advantages by using a broader area of SCS coverage include mitigation against minor lead migration and a reduction in the need for reprogramming. We report here the results of a retrospective case series of 114 patients using Cascade. MATERIALS AND METHODS Retrospective data were collected over two years. We selected patients with neuropathic back with or without/leg pain who had a trial of SCS. Pain assessments using Numerical Rating Scales (NRS) and Patient Global Impression of Change (PGIC) scores were collected at baseline, six months, and last follow-up beyond 12 months (mean 15.1 months). Patients were programmed with 10 kHz SCS using Cascade during the trial, which was continued unless reporting inadequate pain relief. Morbidity and deviations from Cascade programming were also obtained. RESULTS At six months, 87 of 97 (90.6%) patients with active devices were using Cascade and 58 of 72 (81%) patients at the last follow-up >12 months. There was a significant reduction in back NRS (8.3 vs. 3.9 [p 12 months back (8.3 vs. 3.95 [p |
Databáze: | OpenAIRE |
Externí odkaz: |